Prognosis of Patients With Stage III Melanoma According to American Joint Committee on Cancer Version 8: A Reassessment on the Basis of 3 Independent Stage III Melanoma Cohorts
Claus Garbe(University of Tübingen), Alexander M.M. Eggermont(University Medical Center Utrecht), Jochen Utikal(German Cancer Research Center), Anja Gesierich(University of Michigan), Ulrike Keim, Alessandro Testori(European Organisation for Research and Treatment of Cancer), Dirk Schadendorf(National Center for Tumor Diseases), Uwe Wollina(Städtisches Klinikum Dresden), Cord Sunderkötter(MSB Medical School Berlin), Lucie Heinzerling(LMU Klinikum), Axel Hauschild(University Hospital Schleswig-Holstein), Peter Martus(University of Tübingen), Teresa Amaral(University Children's Hospital Tübingen), Thomas Eigentler(University Children's Hospital Tübingen), Ulrich Keilholz(German Cancer Research Center), Thomas Tüting(Otto-von-Guericke-Universität Magdeburg), Stefan Suciu(St James's University Hospital), Ulrike Leiter(University of Tübingen), Rudolf Stadler(University Hospitals of the Ruhr-University of Bochum), Felix Kiecker(Humboldt-Universität zu Berlin), Christos C. Zouboulis(Freie Universität Berlin)
Cited by 71
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Final Version of 2009 AJCC Melanoma Staging and Classification
|Journal of Clinical Oncology|2009|4.6k